Immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1) monoclonal antibody, are approved for use in a variety of tumors, while they had less effects in patients with MSS-CRC [26]. This evidence concerns the gene PDCD1 and colorectal carcinoma.